GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Cyclically Adjusted Revenue per Share

Vertex Pharmaceuticals (BSP:VRTX34) Cyclically Adjusted Revenue per Share : R$36.60 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vertex Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2025 was R$15.367. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$36.60 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Vertex Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 21.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 23.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 26.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 24.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Vertex Pharmaceuticals was 29.90% per year. The lowest was -4.70% per year. And the median was 15.70% per year.

As of today (2025-05-17), Vertex Pharmaceuticals's current stock price is R$616.90. Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was R$36.60. Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 16.86.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vertex Pharmaceuticals was 43.87. The lowest was 14.80. And the median was 23.97.


Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Vertex Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.81 18.12 21.41 24.14 37.29

Vertex Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.47 31.21 31.54 37.29 36.60

Competitive Comparison of Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


;
;

Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vertex Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=15.367/134.9266*134.9266
=15.367

Current CPI (Mar. 2025) = 134.9266.

Vertex Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.537 100.684 0.720
201509 1.249 100.392 1.679
201512 1.669 99.792 2.257
201603 1.509 100.470 2.027
201606 1.511 101.688 2.005
201609 1.374 101.861 1.820
201612 1.569 101.863 2.078
201703 2.247 102.862 2.947
201706 1.781 103.349 2.325
201709 1.809 104.136 2.344
201712 2.092 104.011 2.714
201803 2.032 105.290 2.604
201806 2.742 106.317 3.480
201809 3.102 106.507 3.930
201812 3.251 105.998 4.138
201903 3.168 107.251 3.986
201906 3.492 108.070 4.360
201909 3.755 108.329 4.677
201912 5.530 108.420 6.882
202003 7.023 108.902 8.701
202006 7.507 108.767 9.312
202009 7.864 109.815 9.662
202012 8.006 109.897 9.829
202103 9.275 111.754 11.198
202106 8.638 114.631 10.167
202109 10.083 115.734 11.755
202112 11.406 117.630 13.083
202203 10.118 121.301 11.255
202206 10.713 125.017 11.562
202209 11.792 125.227 12.705
202212 11.601 125.222 12.500
202303 11.880 127.348 12.587
202306 11.618 128.729 12.177
202309 11.766 129.860 12.225
202312 11.825 129.419 12.328
202403 12.829 131.776 13.136
202406 13.802 132.554 14.049
202409 14.703 133.029 14.913
202412 17.262 133.157 17.491
202503 15.367 134.927 15.367

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Vertex Pharmaceuticals  (BSP:VRTX34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vertex Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=616.90/36.60
=16.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vertex Pharmaceuticals was 43.87. The lowest was 14.80. And the median was 23.97.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vertex Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals Business Description

Industry
Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals Headlines

No Headlines